4D Molecular Therapeutics (FDMT) Cash from Financing Activities (2020 - 2026)

4D Molecular Therapeutics (FDMT) has 7 years of Cash from Financing Activities data on file, last reported at $11.5 million in Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at $11.5 million, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $124.4 million (up 575.67% YoY), and the FY2025 annual result was $113.0 million, down 66.51% from the prior year.
• Cash from Financing Activities declined to $11.5 million in Q1 2026 per FDMT's latest filing, from $112.0 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $318.8 million in Q1 2024 and troughed at -$50000.0 in Q2 2022.
• A 5-year average of $38.9 million and a median of $3.4 million in 2022 frame the typical range for Cash from Financing Activities.
• The sharpest annual moves came in 2022 and 2023: Cash from Financing Activities tumbled 106.1% in 2022, then surged 261138.0% in 2023.
• A 5-year view of Cash from Financing Activities shows it stood at $2.0 million in 2022, then soared by 132.75% to $4.8 million in 2023, then tumbled by 87.38% to $601000.0 in 2024, then soared by 18532.61% to $112.0 million in 2025, then tumbled by 89.74% to $11.5 million in 2026.
• Business Quant data shows FDMT's Cash from Financing Activities at $11.5 million in Q1 2026, $112.0 million in Q4 2025, and $116000.0 in Q3 2025.